KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Payables (2018 - 2025)

Twist Bioscience (TWST) has disclosed Payables for 6 consecutive years, with $13.2 million as the latest value for Q1 2023.

  • On a quarterly basis, Payables fell 21.28% to $13.2 million in Q1 2023 year-over-year; TTM through Mar 2023 was $13.2 million, a 21.28% decrease, with the full-year FY2022 number at $20.1 million, up 34.85% from a year prior.
  • Payables was $13.2 million for Q1 2023 at Twist Bioscience, down from $20.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $23.1 million in Q4 2021 to a low of $4.5 million in Q1 2019.
  • A 5-year average of $11.7 million and a median of $9.4 million in 2019 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 50.51% in 2020, then skyrocketed 208.49% in 2021.
  • Twist Bioscience's Payables stood at $9.1 million in 2019, then decreased by 1.91% to $8.9 million in 2020, then skyrocketed by 158.32% to $23.1 million in 2021, then fell by 12.92% to $20.1 million in 2022, then plummeted by 34.12% to $13.2 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Payables are $13.2 million (Q1 2023), $20.1 million (Q3 2022), and $21.0 million (Q2 2022).